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S U M M A R Y
Acute respiratory failure with diffuse pulmonary opacities is an unusual manifestation following
inﬂuenza vaccination. We report herein a patient with chronic obstructive pulmonary disease who
developed fever with worsening of respiratory symptoms and severe hypoxemia requiring ventilatory
support shortly after inﬂuenza vaccination. Bronchoalveolar lavage was compatible with acute
eosinophilic pneumonia. Rapid clinical improvement was observed 2 weeks after systemic
corticosteroid treatment, followed by radiographic improvement at 4 weeks. No disease recurrence
was observed at the 6-month follow-up.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Inﬂuenza vaccination is recommended in the care of patients
with chronic obstructive pulmonary disease (COPD), because it
clearly reduces acute inﬂuenza respiratory illness, late exacerba-
tion of COPD occurring 3–4 weeks after vaccination, and severe
exacerbation requiring mechanical ventilation.1 Although there is
a signiﬁcant increase in the occurrence of local adverse reactions
following vaccination, a life-threatening condition with severe
respiratory distress and diffuse pulmonary opacities rarely occurs.
Only seven cases of inﬂuenza vaccine-induced interstitial lung
disease (ILD) have been reported.2 We report herein the case of an
elderly patient with severe COPD who developed fever with
worsening of respiratory symptoms and severe hypoxemia* Corresponding author. Tel.: +66 (0) 22011629; fax: +66 (0) 22011629.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).requiring ventilatory support shortly after inﬂuenza vaccination.
The diagnosis of acute eosinophilic pneumonia was made by
bronchoscopy and bronchoalveolar lavage (BAL). The clinical
symptoms and radiographic abnormalities improved following
systemic corticosteroid treatment.
2. Case report
An 86-year-old Thai man with severe COPD presented with
increasing breathlessness and fever for 3 days. He also had
generalized malaise, myalgia, and a cough with scant sputum. On
physical examination, his temperature was 38.7 8C, respiratory
rate 26/min, heart rate 90 beats/min, and blood pressure 130/
80 mmHg. His oxygen saturation on room air was 95%. Lung
auscultation revealed coarse crackles and wheezes in the bilateral
lower lungs. Three months prior, he had experienced an acute
COPD exacerbation that had required routine COPD medications
(inhaled salmeterol/ﬂuticasone and ipratropium bromide) and 5ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. (A) Initial chest radiograph obtained 6 days after the inﬂuenza vaccine was administered, showing multi-focal areas of patchy and peribronchial opacities in both
lungs. (B) Chest CT obtained 9 days after the inﬂuenza vaccine was administered, revealing a large area of ground-glass opacities with superimposed interlobular septal
thickening, the so-called crazy-paving appearance (arrow), in the right upper lobe. (C) Chest CT at the level of the lower lungs, showing multi-focal areas of airspace
consolidation in both lungs, with small amounts of bilateral pleural effusion.
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had gradually improved and returned to near baseline over the
next 6 weeks. Other medical conditions included atrial ﬁbrillation
and hypertension treated with aspirin and valsartan.
Seven days prior to this presentation, in March 2012, he
received intramuscular injection of inactivated inﬂuenza vaccine
(Vaxigrip, Sanoﬁ Pasteur) containing of A/California/7/2009
(H1N1) pdm09-like virus, A/Perth/16/2009 (H3N2)-like virus,
and B/Brisbane/60/2008-like virus in his arm. He denied a history
of allergic reaction to any medications or eggs, and exposure to
dust, indoor and outdoor smoke, or fumes and inﬂuenza vaccine.
Initial laboratory tests revealed a white blood cell (WBC) count
of 15.52  109/l (neutrophils 84%, lymphocytes 9%, monocytes 6%,
and eosinophils 1%). Blood chemistry was normal except for
albumin of 19 g/l (normal 34–50 g/l). The initial chest radiograph
revealed multiple patchy and/or peribronchial opacities in both
lungs, notably in the right upper lobe (Figure 1A). Sputum
collection was inadequate for microbiological analysis. Testing
of a nasopharyngeal swab for inﬂuenza and other common
respiratory viruses by multiplex PCR was negative. Intravenous
ceftriaxone and oral azithromycin were given.
Following this treatment, he continued to have daily fever
without clinical improvement, and became more hypoxemic 4
days later. Room air arterial blood gases revealed pH 7.43, pCO2
34.3 mmHg, and pO2 48 mmHg. He subsequently required non-
invasive ventilation and eventually mechanical ventilation. A
computed tomography (CT) scan of the chest (Figure 1, B and C)
revealed multi-focal areas of airspace consolidation involving the
bilateral lower lobes and the right middle lobe, with a large area of
ground-glass opacity with superimposed interlobular septal
thickening in the right upper lobe. He underwent bronchoscopy
with BAL and a transbronchial lung biopsy via the right upper lobe
on day 12 of hospitalization. Analysis of the BAL ﬂuid revealed a
WBC count of 445  106/l (neutrophils, 50%, macrophages, 29%,
lymphocytes, 6%, and eosinophils, 15%). Gram stain, acid-fast
bacillus (AFB) stain, PCR testing for tuberculosis (TB), multiplex
PCR for common respiratory viruses such as adenovirus, coronavi-
rus, respiratory syncytial virus, etc., fungal stain, and bacterial
culture of the BAL ﬂuid were all negative. A repeated blood count
showed a WBC count of 10.2  109/l (neutrophils 73%, lympho-cytes 9%, monocytes 9%, and eosinophils 9%). Fresh smears for
parasites, for example, Strongyloides larvae and Ascaris, were
negative. The transbronchial lung biopsy specimen showed no
evidence of granuloma or malignancy.
All antimicrobials were discontinued, and intravenous dexa-
methasone 5 mg was administered every 12 h. The patient’s fever
subsided and the dyspnoea was markedly improved 48 h after the
treatment. Oral prednisolone 60 mg daily was then given instead. A
follow-up chest CT obtained 4 weeks later revealed substantial
improvement. Oral prednisolone was gradually tapered over the
next 2 weeks. Cultures for TB and fungus from BAL ﬂuid were
negative. He returned to his baseline respiratory condition with
complete resolution of the radiographic abnormalities. No recur-
rence was observed at the 6-month follow-up.
The numbers of interferon gamma (IFN-g)- and interleukin 5
(IL-5)-releasing cells in the peripheral blood were measured by
ELISPOT assay (Mabtech, Sweden) upon stimulation with inﬂuen-
za vaccine. A strong IFN-g response was demonstrated in two
healthy age-matched adults (352 and 478 spots-forming cells
(SFC)/106 peripheral blood mononuclear cells (PBMC), respective-
ly) in whom the same strain of inactivated inﬂuenza vaccine was
given during the same period; in contrast, the magnitude of the
IFN-g response was much lower in this patient (14 SFC/106 PBMC).
The numbers of IL-5-secreting cells were barely detectable in the
patient (2 SFC/106 PBMC), but not found at all in the two control
individuals.
3. Discussion
Inﬂuenza vaccination is currently recommended for every
patient with COPD. Despite its beneﬁts, serious adverse events
following vaccination can occur, including neurological complica-
tions (Guillain–Barre´ syndrome, transverse myelitis) and anaphy-
laxis. Nevertheless, acute respiratory distress with diffuse
pulmonary opacities, as in the present case, is rare.
To date, only seven cases of inﬂuenza vaccine-induced ILD
following pandemic inﬂuenza A (H1N1) and seasonal inﬂuenza
vaccines in 2009 and 2011 have been reported.2 The onset of
respiratory symptoms ranged from 1 to 10 days after vaccination.
The ages of patients ranged from 38 to 75 years. Fever and
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patients had pre-existing lung diseases, including idiopathic
pulmonary ﬁbrosis, lung cancer, post-lobectomy pneumothorax,
and extrinsic allergic alveolitis. One case had no underlying
disease. Six of the seven cases improved after systemic cortico-
steroid administration.
In previous reports, there was an increase in lymphocyte count
in BAL ﬂuid and a lymphocytic inﬁltrate in the lung biopsy
specimens, with positive reaction to inﬂuenza vaccine by drug-
induced lymphocyte stimulation test.2 This is different from our
case, in whom eosinophils were higher than lymphocytes in the
BAL ﬂuid. Although the criteria for the diagnosis of eosinophilic
pneumonia of acute (7 days) or subacute (1 month) duration
requires a BAL eosinophil count of 25%, only severe cases have
met this diagnostic criterion.3 Prior corticosteroid treatment in the
present case might have affected the eosinophil count. The blood
eosinophil count is rarely initially 300/ml, but will increase over
time, as in the present case.
A lung biopsy is generally not required. After possible causes of
eosinophilic pneumonia, including parasitic infestation, drug-
induced eosinophilia, and dust or toxic substance exposure were
excluded, recent exposure to the inﬂuenza vaccine was a plausible
association.
Although the immunopathogenesis of eosinophilic pneumonia
is currently unknown, there is evidence of a Th-2 cytokine-
predominant (IL-5, IL-10, and IL-13) and low Th-1 cytokine (IL-2
and IFN-g) response in this syndrome.4 We speculate that an
aberration of the Th-1/Th-2 axis towards Th-2 against the
inﬂuenza vaccine, conﬁrmed by a very low frequency of inﬂuen-
za-speciﬁc IFN-g releasing cells but comparable IL-5 releasing cells
in this patient, might be responsible, at least in part, for the
development of eosinophilic pneumonia. Additionally, the com-
pensation of other pro-inﬂammatory cytokines such as tumour
necrosis factor (TNF) and IL-1a/b could exert cytokine storm
effects due to a defective inﬂuenza-speciﬁc IFN-g response in thispatient, contributing to the acute lung injury and systemic
inﬂammatory responses. It has previously been demonstrated in
cytokine receptor gene knockout mice that an up-regulation of
other cytokines upon viral infection could be responsible for the
cytokine storm that potentially occurred in these mice.5 Such
hyperinﬂammatory responses possibly manifest as an endothelial
dysfunction with increased pulmonary capillary permeability and
as a sepsis syndrome.
In conclusion, inﬂuenza vaccination may cause a serious
adverse effect in patients with pre-existing chronic respiratory
diseases. Rapid respiratory deterioration with diffuse pulmonary
opacities after vaccination should raise concerns regarding
inﬂuenza vaccine-induced ILD, including acute eosinophilic
pneumonia. Prompt diagnosis and treatment can alleviate this
potentially fatal complication.
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